Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

56.81 -1.49 (-2.56%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,431,315
Open	58.61
Bid (Size)	54.00 (1,000)
Ask (Size)	61.00 (100)
Prev. Close	58.30
Today's Range	56.60 - 58.73
52wk Range	14.36 - 60.10
Shares Outstanding	60,717,176
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....

Via InvestorPlace

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

June 16, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Performance

YTD	+43.8%	+43.8%
1 Month	+26.1%	+26.1%
3 Month	+105.4%	+105.4%
6 Month	+46.1%	+46.1%
1 Year	+283.9%	+283.9%

More News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 11, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

June 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics (NASDAQ:TVTX) Q1 2026 Results Show Record FILSPARI Sales and FSGS Approval, but Revenue and EPS Miss Estimates ↗

May 04, 2026

Via Chartmill

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

June 02, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

May 27, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters ↗

May 10, 2026

Via The Motley Fool

Travere Therapeutics to Participate at Upcoming Investor Conferences

May 07, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 06, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings ↗

May 05, 2026

Via Benzinga

Travere (TVTX) Q1 2026 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Travere Therapeutics Reports First Quarter 2026 Financial Results

May 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere (TVTX) Q2 2025 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Travere (TVTX) Q4 2025 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Travere Therapeutics to Report First Quarter 2026 Financial Results

April 27, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started? ↗

April 20, 2026

Via The Motley Fool

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 14, 2026

From Travere Therapeutics, Inc.

Via Business Wire

These stocks are moving in today's session ↗

April 14, 2026

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

April 14, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

April 14, 2026

Via Chartmill

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

April 13, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases

March 31, 2026

Via MarketMinute

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?

Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Travere Therapeutics, Inc. - Common Stock trade on?

Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?

The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market

What is the current price of Travere Therapeutics, Inc. - Common Stock?

The current price of Travere Therapeutics, Inc. - Common Stock is 56.81

When was Travere Therapeutics, Inc. - Common Stock last traded?

The last trade of Travere Therapeutics, Inc. - Common Stock was at 06/30/26 04:00 PM ET

What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?

The market capitalization of Travere Therapeutics, Inc. - Common Stock is 3.45B

How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?

Travere Therapeutics, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.